Real-world outcomes of encorafenib, cetuximab ± binimetinib for <i>BRAF</i> ‑mutated metastatic colorectal cancer: the BEETS (JACCRO CC‑18) study

In real-world clinical practice, triplet and doublet therapies showed comparable survival outcomes, consistent with the BEACON trial. Triplet therapy may provide potential clinical benefit in patients with poor PFs.